Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

About Momenta Pharmaceuticals

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNTA
  • CUSIP: 60877T10
Key Metrics:
  • Previous Close: $11.98
  • 50 Day Moving Average: $11.90
  • 200 Day Moving Average: $11.15
  • 52-Week Range: $7.86 - $18.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.09
  • P/E Growth: 0.00
  • Market Cap: $821.79M
  • Outstanding Shares: 68,597,000
  • Beta: 1.75
  • Net Margins: -126.37%
  • Return on Equity: -28.76%
  • Return on Assets: -24.23%
  • Current Ratio: 8.36%
  • Quick Ratio: 8.36%
Additional Links:
Companies Related to Momenta Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $16.00 (33.56% upside)

Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateFirmActionRatingPrice TargetDetails
10/11/2016Barclays PLCUpgradeEqual Weight -> Overweight$13.00 -> $19.00View Rating Details
9/7/2016Maxim GroupDowngradeHold -> Sell$6.00View Rating Details
8/7/2016Cowen and CompanyReiterated RatingHoldView Rating Details
8/5/2016JPMorgan Chase & Co.Lower Price TargetOverweight$21.00 -> $15.00View Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$19.00View Rating Details
6/6/2016Goldman Sachs Group Inc.Initiated CoverageNeutral$14.00View Rating Details
5/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $18.00View Rating Details
2/19/2016Stifel NicolausLower Price TargetBuy$29.00 -> $20.00View Rating Details
8/24/2015Sanford C. BernsteinReiterated RatingBuyView Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.32)($0.31)$23.55 million$26.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details
2/17/2015Q414($0.26)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details
7/31/2014Q214($0.46)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details
5/3/2012$0.02($0.10)ViewN/AView Earnings Details
2/9/2012$0.13($0.02)ViewN/AView Earnings Details
11/7/2011$1.28$1.18ViewN/AView Earnings Details
8/4/2011$1.21$1.26ViewN/AView Earnings Details
5/5/2011$0.95$1.13ViewN/AView Earnings Details
2/10/2011$0.81$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)
Current Year EPS Consensus Estimate: $-1.25 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.36)($0.36)($0.36)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)


Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 81.09%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Bruce LeicherSVPSell1,030$12.05$12,411.50View SEC Filing  
8/22/2016Craig A. WheelerPresidentSell5,880$12.02$70,677.60View SEC Filing  
8/22/2016James M RoachVPSell1,091$12.05$13,146.55View SEC Filing  
8/22/2016Richard P SheaCFOSell972$12.05$11,712.60View SEC Filing  
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00View SEC Filing  
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40View SEC Filing  
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00View SEC Filing  
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14View SEC Filing  
5/19/2016John E BishopVPSell784$10.20$7,996.80View SEC Filing  
4/19/2016John E BishopVPSell2,843$9.57$27,207.51View SEC Filing  
2/23/2016John E BishopVPSell329$9.70$3,191.30View SEC Filing  
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55View SEC Filing  
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60View SEC Filing  
2/22/2016John E BishopVPSell2,848$9.66$27,511.68View SEC Filing  
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00View SEC Filing  
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28View SEC Filing  
2/19/2016John E. BishopVPSell357$10.28$3,669.96View SEC Filing  
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72View SEC Filing  
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13View SEC Filing  
2/18/2016James M RoachVPSell272$10.49$2,853.28View SEC Filing  
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67View SEC Filing  
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40View SEC Filing  
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.80View SEC Filing  
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76View SEC Filing  
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05View SEC Filing  
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20View SEC Filing  
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00View SEC Filing  
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48View SEC Filing  
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22View SEC Filing  
8/19/2015James M. RoachVPSell7,011$22.09$154,872.99View SEC Filing  
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82View SEC Filing  
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04View SEC Filing  
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83View SEC Filing  
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23View SEC Filing  
2/24/2014John BishopVPSell1,038$17.67$18,341.46View SEC Filing  
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30View SEC Filing  
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00View SEC Filing  
1/9/2014John BishopVPSell27,159$19.50$529,600.50View SEC Filing  
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00View SEC Filing  
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55View SEC Filing  
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22View SEC Filing  
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55View SEC Filing  
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36View SEC Filing  
10/11/2013John BishopVPSell5,247$15.46$81,118.62View SEC Filing  
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10View SEC Filing  
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23View SEC Filing  
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84View SEC Filing  
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)
News IconAn intrinsic value calculation for Momenta Pharmaceuticals Inc (MNTA) shows investors are overpaying - Simply Wall St (NASDAQ:MNTA) - October 21 at 9:36 AM
News IconToday's Pattern Action: Momenta Pharmaceuticals, Inc. Could Help ... - Chester News (NASDAQ:MNTA) - October 20 at 11:56 AM logoMomenta Pharmaceuticals Announces Date for Third Quarter 2016 Financial Results Conference Call and Webcast (NASDAQ:MNTA) - October 20 at 11:56 AM logo7 Drug Stocks to Consider as Biosimilars Pick Up Pace (NASDAQ:MNTA) - October 20 at 11:56 AM logoMomenta Phama (MNTA) Chief Medical Officer, SVP Roach Resigns (NASDAQ:MNTA) - October 19 at 6:33 PM
News IconMomenta Pharmaceuticals (MNTA) Stock: Here’s The What, Why & What’s Next! (NASDAQ:MNTA) - October 19 at 6:33 PM
News IconLatest Analyst Ratings For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - The De Soto Edge (NASDAQ:MNTA) - October 16 at 5:59 PM
News IconStock Update: Estimates & Target in Focus for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - CSZ News (NASDAQ:MNTA) - October 13 at 6:17 PM logoA Compelling Risk/Reward Seen In Momenta Pharmaceuticals - Benzinga (NASDAQ:MNTA) - October 13 at 6:17 PM
News IconAnalyst Opinion of: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) - TRA (NASDAQ:MNTA) - October 13 at 9:47 AM logoMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Sales Estimate At $297.395 - Investor Newswire (NASDAQ:MNTA) - October 13 at 9:47 AM
News IconMomenta Pharmaceuticals Inc. (MNTA) Climbed To A 6-Week High After Upgrade - Cosumnes Connection (subscription) (NASDAQ:MNTA) - October 13 at 9:47 AM
News IconCalifornia Public Employees Retirement System Reduced the ... - DailyQuint (NASDAQ:MNTA) - October 12 at 6:11 PM
News IconMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Boosted by Analyst Upgrade - Scibility Media (NASDAQ:MNTA) - October 12 at 6:11 PM logoMomenta Pharmaceuticals Inc. (MNTA) Climbed To A 6-Week High After Upgrade (NASDAQ:MNTA) - October 12 at 11:33 AM
News IconMomenta Pharmaceuticals (MNTA) Surges on Barclays Upgrade (NASDAQ:MNTA) - October 12 at 11:33 AM logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : October 12, 2016 (NASDAQ:MNTA) - October 12 at 11:33 AM logoMomenta Pharmaceuticals (MNTA) Jumps: Stock Up 12.7% (NASDAQ:MNTA) - October 12 at 11:33 AM logoA Compelling Risk/Reward Seen In Momenta Pharmaceuticals (NASDAQ:MNTA) - October 11 at 6:29 PM logoMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Stock Price Estimate At $14.375 - Investor Newswire (NASDAQ:MNTA) - October 9 at 10:30 AM
News IconIs there Upside to Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) ? - Recall News (NASDAQ:MNTA) - October 4 at 10:57 AM
News IconWhat is the Sell-side Saying About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)? - Frisco Fastball (NASDAQ:MNTA) - October 1 at 11:32 AM
News IconAnalyst Coverage: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA ... - NewsDen (NASDAQ:MNTA) - October 1 at 11:32 AM
News IconMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) – Broker Update - NewsDen (NASDAQ:MNTA) - October 1 at 11:32 AM
News IconShares Slipping Lower Over the Past Month: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) - Post News (NASDAQ:MNTA) - September 29 at 11:21 AM
News IconMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Updated Broker Price Targets - The De Soto Edge (NASDAQ:MNTA) - September 29 at 11:21 AM logoCoherus, Momenta Set for Different Outcomes - Barron's (NASDAQ:MNTA) - September 28 at 5:58 PM logoMomenta Pharmaceuticals to Regain Global Development and Commercialization Rights to M923, a Proposed ... - GlobeNewswire (press release) (NASDAQ:MNTA) - September 28 at 11:11 AM logoShire (SHPG) Terminates HUMIRA Biosimilar Collaboration Agreement with Momenta Phama (MNTA) - (NASDAQ:MNTA) - September 28 at 11:11 AM
News IconBlog Coverage Shire PLC Terminates Collaboration Agreement with Momenta Pharma for M923 (NASDAQ:MNTA) - September 28 at 11:11 AM logoMomenta to Regain Rights to Humira Biosimilar from Shire (NASDAQ:MNTA) - September 28 at 11:11 AM logoMomenta Pharmaceuticals to Regain Global Development and Commercialization Rights to M923, a Proposed Biosimilar of HUMIRA® (adalimumab), Through Termination of Collaboration Agreement with Baxalta, Now Part of Shire (NASDAQ:MNTA) - September 27 at 10:48 AM logo8:01 am Momenta Pharma announces that Shire (SHPG (NASDAQ:MNTA) - September 27 at 10:48 AM logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : September 27, 2016 (NASDAQ:MNTA) - September 27 at 10:48 AM logoMOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement (NASDAQ:MNTA) - September 27 at 10:48 AM logoMomenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors - GlobeNewswire (press release) (NASDAQ:MNTA) - September 23 at 10:53 AM logoMOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MNTA) - September 23 at 10:53 AM logoMomenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors (NASDAQ:MNTA) - September 23 at 10:53 AM logoBIOFACTURA ANNOUNCES ENTRY INTO NON-EXCLUSIVE LICENSE AGREEMENT WITH MOMENTA PHARMACEUTICALS (NASDAQ:MNTA) - September 22 at 5:55 PM logoBIOFACTURA ANNOUNCES ENTRY INTO NON-EXCLUSIVE LICENSE AGREEMENT WITH MOMENTA PHARMACEUTICALS (NASDAQ:MNTA) - September 22 at 5:55 PM logoMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA)'s Expectation Of $297.395 In Sales - Investor Newswire (NASDAQ:MNTA) - September 22 at 10:59 AM
News IconMomenta Pharmaceuticals Given Average Rating of “Buy” by ... - Petro Global News 24 (NASDAQ:MNTA) - September 22 at 10:59 AM
News IconMomenta Pharmaceuticals Inc. (NASDAQ:MNTA) earnings reaction ... - The Independent Republic (NASDAQ:MNTA) - September 22 at 10:59 AM
News IconGoldman Sachs Begins Coverage on Momenta Pharmaceuticals, Inc. (MNTA) - DailyQuint (NASDAQ:MNTA) - September 20 at 11:21 AM logoMOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:MNTA) - September 19 at 6:10 PM
News IconBrokerages Expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA ... - DailyQuint (NASDAQ:MNTA) - September 18 at 10:33 AM logoMomenta Pharmaceuticals : How These Generic Drugs Stocks are Faring? -- Evoke Pharma, Mallinckrodt, Catalyst Pharma, and Momenta Pharma (NASDAQ:MNTA) - September 15 at 9:39 AM logoExpected For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Sales Of $297.395 - Investor Newswire (NASDAQ:MNTA) - September 14 at 6:20 PM logoMomenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : September 13, 2016 (NASDAQ:MNTA) - September 14 at 10:28 AM logoTwo Things You Must Understand About Biotech Investing (NASDAQ:MNTA) - September 12 at 5:56 PM


Momenta Pharmaceuticals (NASDAQ:MNTA) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by Staff